{"transactions":[{"id":4436,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":100485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":100485},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4435,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":502423,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":100485},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4434,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":208974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2023-05-12","expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":208974},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4433,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":208974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":393934,"derivative":{"exercise_price":0.053,"exercise_date":"2023-05-12","expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":208974},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4432,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":90529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2022-10-05","expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":90529},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4431,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":512379,"derivative":{"exercise_price":0.16,"exercise_date":"2022-10-05","expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":90529},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4430,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":65620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2022-04-12","expiration_date":"2032-04-11","underlying":"Common Stock","underlying_shares":65620},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4429,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":537288,"derivative":{"exercise_price":0.16,"exercise_date":"2022-04-12","expiration_date":"2032-04-11","underlying":"Common Stock","underlying_shares":65620},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4428,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2021-05-17","expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4427,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":572908,"derivative":{"exercise_price":0.16,"exercise_date":"2021-05-17","expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4426,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2020-04-01","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4425,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":592908,"derivative":{"exercise_price":0.16,"exercise_date":"2020-04-01","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4424,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":59530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2018-06-01","expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":59530},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4423,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":543378,"derivative":{"exercise_price":0.16,"exercise_date":"2018-06-01","expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":59530},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4422,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":37770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2018-01-08","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":37770},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4421,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":565138,"derivative":{"exercise_price":0.16,"exercise_date":"2018-01-08","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":37770},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4406,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10049,"kind":"person","name":"Kalinichev Mikhail","position":1,"cik":"0002123907","reported_name":"Kalinichev Mikhail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF TRANSLATIONAL SCIENCE"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:09:46.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":200000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-26-105506","document":"tm2624769-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2123907/000110465926105506/tm2624769-9_4seq1.xml","form_type":"4"}},{"id":4405,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10049,"kind":"person","name":"Kalinichev Mikhail","position":1,"cik":"0002123907","reported_name":"Kalinichev Mikhail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF TRANSLATIONAL SCIENCE"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:09:46.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-26-105506","document":"tm2624769-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2123907/000110465926105506/tm2624769-9_4seq1.xml","form_type":"4"}},{"id":4404,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10049,"kind":"person","name":"Kalinichev Mikhail","position":1,"cik":"0002123907","reported_name":"Kalinichev Mikhail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF TRANSLATIONAL SCIENCE"}}],"security":"Common Stock","published_at":"2026-09-04T20:09:46.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":306765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":306765,"source":{"system":"sec-edgar","filing":"0001104659-26-105506","document":"tm2624769-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2123907/000110465926105506/tm2624769-9_4seq1.xml","form_type":"4"}},{"id":4403,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10049,"kind":"person","name":"Kalinichev Mikhail","position":1,"cik":"0002123907","reported_name":"Kalinichev Mikhail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF TRANSLATIONAL SCIENCE"}}],"security":"Common Stock","published_at":"2026-09-04T20:09:46.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":306765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105506","document":"tm2624769-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2123907/000110465926105506/tm2624769-9_4seq1.xml","form_type":"4"}},{"id":4382,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4381,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4380,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":219561,"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4379,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4354,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4353,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4352,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":392837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"}],"balance_after":785976,"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4351,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":392837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"}],"balance_after":393139,"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4317,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4316,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4315,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":219561,"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4314,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10002,"kind":"person","name":"Manke Isaac","position":1,"cik":"0001622769","reported_name":"Manke Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:03:30.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105491","document":"tm2624769-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622769/000110465926105491/tm2624769-3_4seq1.xml","form_type":"4"}},{"id":4310,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9998,"kind":"person","name":"Lawton Vincent Michael","position":1,"cik":"0002123870","reported_name":"Lawton Vincent Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:02:09.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":501598,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":501598,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":501598},"source":{"system":"sec-edgar","filing":"0001104659-26-105489","document":"tm2624769-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2123870/000110465926105489/tm2624769-8_4seq1.xml","form_type":"4"}},{"id":4309,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9998,"kind":"person","name":"Lawton Vincent Michael","position":1,"cik":"0002123870","reported_name":"Lawton Vincent Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:02:09.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":501598,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":501598},"source":{"system":"sec-edgar","filing":"0001104659-26-105489","document":"tm2624769-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2123870/000110465926105489/tm2624769-8_4seq1.xml","form_type":"4"}},{"id":4308,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9998,"kind":"person","name":"Lawton Vincent Michael","position":1,"cik":"0002123870","reported_name":"Lawton Vincent Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:02:09.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":2507487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 2,507,487 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 1,464,334 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 1,043,153 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 2,507,487 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 1,464,334 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 1,043,153 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":2507987,"source":{"system":"sec-edgar","filing":"0001104659-26-105489","document":"tm2624769-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2123870/000110465926105489/tm2624769-8_4seq1.xml","form_type":"4"}},{"id":4307,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9998,"kind":"person","name":"Lawton Vincent Michael","position":1,"cik":"0002123870","reported_name":"Lawton Vincent Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:02:09.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2507487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 2,507,487 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 1,464,334 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 1,043,153 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 2,507,487 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 1,464,334 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 1,043,153 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001104659-26-105489","document":"tm2624769-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2123870/000110465926105489/tm2624769-8_4seq1.xml","form_type":"4"}},{"id":4297,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9994,"kind":"person","name":"Hill Raymond George","position":1,"cik":"0002123864","reported_name":"Hill Raymond George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:01:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":273107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":273107,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":273107},"source":{"system":"sec-edgar","filing":"0001104659-26-105484","document":"tm2624769-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2123864/000110465926105484/tm2624769-6_4seq1.xml","form_type":"4"}},{"id":4296,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9994,"kind":"person","name":"Hill Raymond George","position":1,"cik":"0002123864","reported_name":"Hill Raymond George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:01:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":273107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":273107},"source":{"system":"sec-edgar","filing":"0001104659-26-105484","document":"tm2624769-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2123864/000110465926105484/tm2624769-6_4seq1.xml","form_type":"4"}},{"id":4295,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9994,"kind":"person","name":"Hill Raymond George","position":1,"cik":"0002123864","reported_name":"Hill Raymond George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:01:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":1365532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 1,365,532 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 797,563 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 567,969 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 1,365,532 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 797,563 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 567,969 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":1365532,"source":{"system":"sec-edgar","filing":"0001104659-26-105484","document":"tm2624769-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2123864/000110465926105484/tm2624769-6_4seq1.xml","form_type":"4"}},{"id":4294,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9994,"kind":"person","name":"Hill Raymond George","position":1,"cik":"0002123864","reported_name":"Hill Raymond George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:01:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1365532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 1,365,532 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 797,563 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 567,969 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 1,365,532 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 797,563 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 567,969 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105484","document":"tm2624769-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2123864/000110465926105484/tm2624769-6_4seq1.xml","form_type":"4"}},{"id":4289,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9990,"kind":"person","name":"Dyer Timothy Mark","position":1,"cik":"0001830908","reported_name":"Dyer Timothy Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:00:10.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":3369796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":3369796,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":3369796},"source":{"system":"sec-edgar","filing":"0001104659-26-105481","document":"tm2624769-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1830908/000110465926105481/tm2624769-2_4seq1.xml","form_type":"4"}},{"id":4288,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9990,"kind":"person","name":"Dyer Timothy Mark","position":1,"cik":"0001830908","reported_name":"Dyer Timothy Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:00:10.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3369796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":3369796},"source":{"system":"sec-edgar","filing":"0001104659-26-105481","document":"tm2624769-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1830908/000110465926105481/tm2624769-2_4seq1.xml","form_type":"4"}},{"id":4287,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9990,"kind":"person","name":"Dyer Timothy Mark","position":1,"cik":"0001830908","reported_name":"Dyer Timothy Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:00:10.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":16413787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 16,413,787 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 9,405,754 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 7,008,033 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 16,413,787 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 9,405,754 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 7,008,033 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":16848979,"source":{"system":"sec-edgar","filing":"0001104659-26-105481","document":"tm2624769-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1830908/000110465926105481/tm2624769-2_4seq1.xml","form_type":"4"}},{"id":4286,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":9990,"kind":"person","name":"Dyer Timothy Mark","position":1,"cik":"0001830908","reported_name":"Dyer Timothy Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:00:10.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16413787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 16,413,787 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 9,405,754 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 7,008,033 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 16,413,787 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 9,405,754 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 7,008,033 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":435192,"source":{"system":"sec-edgar","filing":"0001104659-26-105481","document":"tm2624769-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1830908/000110465926105481/tm2624769-2_4seq1.xml","form_type":"4"}}]}